The effect of Taurolidine on adherent and floating subpopulations of melanoma cells

Anti-Cancer Drugs

Volumn 14, Issue 4, 2003, Pages 295-303

  Shrayer, D P ^a,b   Lukoff, H ^a   King, T ^a   Calabresi, P ^a  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Apoptosis; Cell cycle; Cytotoxicity; Melanoma; Taurolidine

Indexed keywords

DNA FRAGMENT; TAUROLIDINE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER INCIDENCE; CANCER INHIBITION; CELL ADHESION; CELL CYCLE; CELL STRUCTURE; CELL SUBPOPULATION; CELL SWELLING; CONTROLLED STUDY; HUMAN; HUMAN CELL; IC 50; MELANOMA CELL; NONHUMAN; PHASE CONTRAST MICROSCOPY; PRIORITY JOURNAL;

ANIMALS; ANNEXIN A5; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MELANOMA; MICE; NEOPLASM METASTASIS; PROTEIN BINDING; TAURINE; THIADIAZINES; TUMOR CELLS, CULTURED;

EID: 0037568201     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200304000-00007     Document Type: Article

References (50)

1. Milic S, Wicki O. Abdominal trauma and sepsis. Helv Chir Acta 1976; 43:707-709.
2. Wicki O, Pfizrmann RW. Taurolin in peritonitis. In: Local Management of Surgical Infection. Stuttgart: Verlag Hans Huber; 1979, pp. 42-48.
3. Marti MC, Moser G, Wicki O, et al. Intravenous and intraperitoneal administration of an antiseptic, 65 cases of peritonitis treated with Taurolin. Helv Chir Acta 1979; 46:755-758.
4. Del Ponte F. The treatment of suppurative peritonitis with Taurolin a new chemotherapeutic drug with antiendotoxin action. Rivista Medica della Svizzena Italiana 1979; 533-535.
5. Ruesgegger CH, Mosimann R. Prophylaxis with antibiotics versus Taurolidine used perioperative in surgery of the colon - a comparative study. Helv Chir Acta 1983; 50:117-120.
6. Lob G, Burri C. Perioperative wound irrigation - a comparison between 1% Taurolin and Nebacein. In: Briickuer WL, Pfirrmann RW (editors): Taurolin - A New Concept in Antimicrobial Chemotherapy for Surgical Infection. Munich: Urban & Schwarznenberg; 1985, pp. 136-142.
7. Bedrosian I, Sofia R, Wolff SM, Dinorello CA. Taurolidine, an analogue of the amino acid taurine, suppresses interleukin I and tumor necrosis factor synthesis in human peripheral blood mononuclear cells. Cytokines 1991; 3:568-575.
8. Reiumeller J. The influence of Taurolidine on physiological and pathological coagulation and the implications for its use. Z Chiz 1999; 124:13-18.
9. Jacobi CA, Ordemam J, Bohm B, Sierea HU, Sabat R, Miller JM. Inhibition of peritoneal tumor cell growth and implantation in laparoscopic surgery in a rat model. Am J Surg 1997; 174:359-363.
10. Calabresi P, Goulette FA, Darnowski JW. Antineoplastic effects of Taurolidine in human tumor cell lines. Proc Am Ass Cancer Res 2000; 771: abstr 4899.
11. Darnowski JW, Goulette FA, Calabresi P. Taurolidine induces apoptosis in the androgen-independent DU145 human prostate tumor cell line. In: Proc 5th Int Conf Geriatric Oncology Cancer in the Elderly, New York; 2000, #10.
12. Ribizzi I, Darnowski JW, Goulette FA, Calabresi P. Tauroldine: a novel and safe cytotoxic agent for elderly patients with myelodyplastic syndrome. In: Proc 5th Int Conf Geriatric Oncology Cancer in the Elderly, New York; 2000, #9.
13. Shrayer D, Lukoff H, Wagner E, Goulette F, Darnowski JW, Calabresi P. Treatment of early stage and established primary melanoma by Taurolidine. In: Proc 5th Int Conf Geriatric Oncology Cancer in the Elderly, New York; 2000, #11.
14. Carmichael JD, DeGraft WG, Gazder AF, Miung JD, Michell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987; 47:936-942.
15. Nakanishi O, Baba M, Saito A, et al. Potentiation of the antitumor activity by a novel quinoline compound MS-209 in multi-drug resistant solid tumor cell lines. Oncol Res 1997; 9:61-69.
16. Hawthorne TR, Austin JK. Synergism of the polyacerine analogue, N1,N11-bisethylnorspermine with cis-diaminedichloroplatinum II against murine neoplastic cell lines in vitro and in vivo. Cancer Lett 1996; 99:99-107.
17. Chapman RS, Whetton WD, Dive C. The suppression of drug-induced apoptosis by activation of V-ABL protein tyrosine kinase. Cancer Res 1994; 54:5131-5141.
18. Shrayer DP, Kouttab N, Hearing V, Wanebo HJ. Immunization of mice with melanoma cells transfected to secrete the superantigen, staphylococcal enterotoxin A. Cancer Immunol 1998; 46:7-13.
19. Sriwivas G, Kusumokumary P, Nair MK, Pacricher KR, Pillai MR. Mutant p53 protein, Bcl-2/Bax ratios and apoptosis in pediatric acute lymphoblastic leukemia. Cancer Res Clin Oncol 2000; 126:62-67.
20. Davol PA, Goulette FA, Frackelton Jr AR, Darnowski JW. Modification of p53 expression by human recombinant interferon-2a correlates with abrogation of cisplatin resistance in human melanoma cell line. Cancer Res 1996; 56:2522-2526.
21. Cattanco-Pangrarri RMC, Schott H, Wunderli-Allenspach H, Rothen-Rutishauser B, Guentheri M, Schwendener RA. Cell cycle arrest and p53-independent induction of apoptosis in vitro by the new anticancer drugs 5-FdU2d-FdCydOct in vitro and dCyd-Pan-P-FdCydOct and dCyd-Pan-P-FdU2d in DU145 human prostate cancer cells. Cancer Res Clin Oncol 2000; 126:247-256.
22. Metha S, Blackinton D, Omar I, Kouttab N, Myrick D, Klostergaard S, et al. Combined cytotoxic action of paclitaxel and ceramide against the human TU 138 head and neck squamous carcinoma cell line. Cancer Chemother Pharmacol 2000; 46:85-92.
23. Kuwashima Y, Matsubara O, Kasuda T. Responses of murine B16 melanoma to pharmacotherapy studied and compared with different assay systems. J Cancer Res Oncol 1990; 116:173-178.
24. Meyn RE, Stephens LC, Hunter NR, Milas L. Induction of apoptosis in murine tumors by cyclophosphamide. Cancer Chemother Pharmacol 1994; 33:410-414.
25. Kerr JFR, Winterford CH, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994; 73:2013-2026.
26. Majno C, Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol 1995; 146:3-15.
27. Kuwashima Y. Cytomorphology of murine B16 melanoma in vivo after treatment with cyclophosphamide: evidence of oncotic cell death. Anticancer Res 1996; 16:2997-3000.
28. Maurer BS, Metelitsa LS, Seeger RC, Cabot MC, Reynolds CP. Increase of ceramide and induction of mixed apoptosis and necrosis by N-14-hydroxyphenyl-retimamide in neuroblastoma cell lines. J Natl Cancer Inst 1999; 91:1138-1146.
29. Koyama S, Tanaka S, Haniu H, Yamaguchi Y, Motoyoshiya J. YoshixolTR inhibits B16 melanoma cell growth in vivo and induces apoptosis-like (quantum thermodynamic) cell death. Gen Pharmacol 1999; 33:161-172.
30. Mo H, Elson CE. Apoptosis and cell-cycle arrest in human and murine tumor cells are initiated by isoprenoids. J Nutr 1999; 129:804-813.
31. Montaldo PG, Pagnan G, Pastorino F, Chiesa V, Raffaghello L, Kirchmeier M, et al. N-(4-hydroxyphenyl) retimamide is cytotoxic to melanoma cells in vitro through induction of programmed cell death. Int J Cancer 1999; 81:262-267.
32. Iwashita K, Kobori M, Yamaki K, Tsushida T. Flavonoids inhibit cell growth and induce apoptosis in B16 melanoma 4A5 cells. Biosci Biotechnol Biochem 2000; 64:1813-1820.
33. Ko WG, Kang TH, Kim NY, Lee SJ, Kim YC, Ko GI, et al. Lavandulyl flavonoids: a new class of in vitro apoptogenic agents from Sophora flavoscens. Toxicol in vitro 2000; 14:429-433.
34. Mo H, Tatman D, Jung M, Elson CE. Farnesyl anthranilate suppresses the growth, in vitro and in vivo, of murine B16 melanoma. Cancer Lett 2000; 157:145-153.
35. Pantazis P, Chatterjee D, Han Z, Wyche J. Differentiation of human malignant melanoma cells that escape apoptosis after treatment with 9-nitrocamptothecin in vitro. Neoplasia 1999; 1:231-240.
36. Moinet-Hedin V, Tabka T, Poulain L, Godard T, Lechevrel M, Saturnino C, et al. Biological properties of 5,11-dimethyl-6H-pyrido[3,2-b]carbazoles: a new class of potent antitumour drugs. Anticancer Drug Des 2000; 15:109-118.
37. Kalechman Y, Longo DL, Catane R, Shani A, Albeck M, Shredni B. Synergistic anti-tumor effect of paclitaxel (taxol) + AS101 in a murine model of B16 melanoma: association with ras-dependent signal-transduction pathways. Int J Cancer 2000; 86:281-288.
38. Shapiro GI, Koestner DA, Matranga CB, Rollins BJ. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res 1999; 5:2925-2938.
39. 1 arrest induced by irradiation and/or hyperthermia in six human tumor cell lines of different p53 status. Int J Radiat Biol 2000; 76:717-725.
40. Serafino A, Sinibaldi-Vallebona P, Pierimarchi P, Gaudiano G, Massa C, Rasi G, et al. Induction of apoptosis in neoplastic cells by anthracycline antitumor drugs: nuclear and cytoplasmic triggering? Anticancer Res 1999; 19:1909-1918.
41. Valyi-Nagy I, Shih IM, Gyorfi T, Greenstein D, Juhasz I, Elder DE, et al. Spontaneous and induced differentiation of human melanoma cells. Int J Cancer 1993; 54:159-165.
42. Rofstad EK. Radiation sensitivity in vitro of primary tumors and metastatic lesions of malignant melanoma. Cancer Res 1992; 52:4453-4457.
43. Schittek B, Blaheta HJ, Ellwanger U, Garbe C. Polymerase chain reaction in the detection of circulating tumor cells in peripheral blood of melanoma patients. Rec Res Cancer Res 2001; 158:93-104.
44. Schrader AJ, Probst-Kepper M, Grosse J, Kunter U, Franzke A, Sel S, et al. Tumor microdissemination and survival in metastatic melanoma. Anticancer Res 2000; 20:3619-3624.
45. Benez A, Schiebel U, Fierlbeck G. Morphologically intact melanoma cells may be detected in peripheral blood of melanoma patients. Rec Res Cancer Res 2001; 158:113-117.
46. Barnhill RI. The biology of melanoma micrometastases. Rec Res Cancer Res 2001; 158:3-13.
47. Yamamura K, Kibbey MC, Kleinman HK. Melanoma cells selected for adhesion to laminin peptides have different malignant properties. Cancer Res 1993; 53:423-428.
48. Eves P, Layton C, Hedley S, Dawson RA, Wagner M, Morandini R, et al. Characterization of an in vitro model of human melanoma invasion based on reconstructed human skin. Br J Dermatol 2000; 142:210-222.
49. Wong CW, Lee A, Shientag L, Yu J, Dong Y, Kao G, et al. Apoptosis: an early event in metastatic inefficiency. Cancer Res 2000; 61:333-338.
50. Cascinelli N, Heerlyn M, Schneeberger A, Kuwert C, Slonimski A, Armstrong C, et al. What is the most promising strategy for the treatment of metastasizing melanoma? Exp Dermatol 2000; 9:439-451.